Hyperphosphatemia Epidemiology Forecast Report 2021-2030 – ResearchAndMarkets.com

Hyperphosphatemia Epidemiology Forecast Report 2021-2030 – ResearchAndMarkets.com




Hyperphosphatemia Epidemiology Forecast Report 2021-2030 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Hyperphosphatemia – Epidemiology Forecast to 2030” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This ‘Hyperphosphatemia – Epidemiology Forecast – 2030’ report delivers an in-depth understanding of the Hyperphosphatemia, historical and forecasted epidemiology as well as the Hyperphosphatemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), Japan, China and Taiwan.

Hyperphosphatemia Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Prevalent Cases of Chronic Kidney Disease, Diagnosed Prevalent Cases of Chronic Kidney Disease, Stage-specific Distribution of Chronic Kidney Disease, Prevalent Cases of End-Stage Renal Disease, Number of ESRD Patients Undergoing Dialysis and Prevalent Cases of Hyperphosphatemia in the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), Japan, China and Taiwan from 2018 to 2030.

Key Findings

This section provides glimpse of the Hyperphosphatemia epidemiology in the 7MM, China and Taiwan.

  • The total diagnosed prevalent cases of chronic kidney disease (CKD) in the seven major markets, China and Taiwan was estimated to be 27,063,599 in 2020.
  • In the United States, the patients with Stage 3-5 CKD accounted for 2,317,671 in 2020.
  • In 2020, in the United States, the prevalence of ESRD was 797,101 and patients with ESRD on dialysis accounted for 565,941 cases.
  • The total prevalent population of hyperphosphatemia in the 7 MM, China and Taiwan is expected to increase at a CAGR of 0.42% during the forecast period 2021-2030.
  • The United States, in 2020, accounted for 481,050 prevalent cases of hyperphosphatemia in ESRD patients undergoing dialysis. Among EU5 countries, Germany had the highest number of prevalent cases of hyperphosphatemia in ESRD patients undergoing dialysis, which were 55,631 in 2020. Whereas, Spain accounted for the least number of prevalent cases of hyperphosphatemia in ESRD patients undergoing dialysis, which were 23,847 in 2020.
  • Japan, China and Taiwan in 2020, accounted for 283,831, 487,163 and 73,208 prevalent cases of hyperphosphatemia.

Analyst Comments

  • Our forecast model has taken the chronic kidney disease prevalence of nearly 15.45% of the adult US population. Furthermore, ESRD affect 2 in every 1,000 people, and among them, 71% are on dialysis, and 29% are living with a kidney transplant. Apart from this rate, we have estimated ESRD diagnosed pool separately from the various published literature and kidney disease registries. We also analyzed various published literature and studies for the estimation of the total prevalence of CKD.
  • To estimate CKD prevalence in Germany, we have taken prevalence of 17.30% for Germany, 10% for France, 8.50% for Italy, 12.50% for Spain, 13.50% for the UK of the total adult country population. Furthermore, we have separately estimated the diagnosed ESRD patient pool based on the number of patients treated by Renal Replacement Therapy, including Dialysis and Kidney Transplantation.

Key Questions Answered

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of Hyperphosphatemia?
  • What is the historical Hyperphosphatemia patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), Japan, China and Taiwan?
  • What would be the forecasted patient pool of Hyperphosphatemia at the 7MM, China and Taiwan level?
  • What will be the growth opportunities across the 7MM, China and Taiwan with respect to the patient population pertaining to Hyperphosphatemia?
  • Out of the above-mentioned countries, which country would have the highest prevalent population of Hyperphosphatemia during the forecast period (2021-2030)?
  • At what CAGR the population is expected to grow across the 7MM, China and Taiwan during the forecast period (2021-2030)?

Key Topics Covered:

1 Key Insights

2 Table of Contents

3 List of Tables

4 List of Figure

5 Hyperphosphatemia Overview at a Glance

5.1 Patient Share (%) Distribution of Hyperphosphatemia in 2020

5.2 Patient Share (%) Distribution of Hyperphosphatemia in 2030

6 Executive Summary

7 SWOT Analysis

8 Disease Background and Overview

8.1 Introduction

8.2 Signs and Symptoms

8.3 Causes

8.4 Risk and Complications

8.5 Pathophysiology

8.6 Prognosis

8.7 Prevention

8.8 Diagnosis and Differential Diagnosis

9 Epidemiology and Patient Population

9.1 Key Findings

9.2 Assumptions and Rationale

9.3 Total Prevalent Cases of Hyperphosphatemia in the 7MM, China, and Taiwan

9.4 The United States

9.5 EU5 Countries

9.6 Germany

9.7 France

9.8 Italy

9.9 Spain

9.10 United Kingdom

9.11 Japan

9.12 China

9.13 Taiwan

10 Recognized Establishments

11 Case Reports

12 KOL Views

13 Appendix

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/jtza4y

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900